<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062049</url>
  </required_header>
  <id_info>
    <org_study_id>030152</org_study_id>
    <secondary_id>03-C-0152I</secondary_id>
    <secondary_id>CDR0000304451</secondary_id>
    <nct_id>NCT00062049</nct_id>
    <nct_alias>NCT00059059</nct_alias>
  </id_info>
  <brief_title>Interleukin-7 in Treating Patients With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Subcutaneous &quot;CYT 99 007&quot; (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in&#xD;
      treating patients with refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and dose-limiting toxicity of biologically active doses of&#xD;
           interleukin-7 in patients with refractory solid tumors.&#xD;
&#xD;
        -  Determine a range of biologically active doses of this drug in these patients.&#xD;
&#xD;
        -  Determine the biological effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.&#xD;
&#xD;
        -  Determine the antitumor effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive interleukin-7 (IL-7) subcutaneously on days 0, 2, 4, 6, 8, 10, 12, and 14&#xD;
      (for a total of 8 doses) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of IL-7 until the maximum tolerated dose&#xD;
      (MTD) and &quot;biologically active dose&quot; (BAD) are determined. The MTD is defined as the dose&#xD;
      preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
      The BAD is defined as the dose that produces a sustained 50% increase in CD3+ count over the&#xD;
      patient's baseline without unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1, 3, and 6 months and at 1 year after study completion.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 3.75-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-7</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignancy meeting both of the following criteria:&#xD;
&#xD;
               -  No known curative therapy&#xD;
&#xD;
               -  Failed standard therapy, defined as either lack of response OR disease&#xD;
                  progression (i.e., at least 25% increase in disease or new disease)&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No hematopoietic malignancies&#xD;
&#xD;
          -  No primary carcinoma of the lung&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No proliferative hematologic disease&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times ULN&#xD;
&#xD;
          -  No documented hepatitis B infection&#xD;
&#xD;
          -  No documented hepatitis C infection&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction greater than 45% by MUGA&#xD;
&#xD;
          -  Hypertension (resting blood pressure greater than 140/90 mm Hg) must be controlled&#xD;
             with standard anti-hypertensive therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe asthma&#xD;
&#xD;
          -  DLCO/VA greater than 50% of predicted&#xD;
&#xD;
          -  FEV_1 greater than 50% of predicted&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  Peripheral CD3+ cell count greater than 300/mm^3 and stable on 4 successive&#xD;
             determinations&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other medical or psychiatric condition that would preclude study compliance&#xD;
&#xD;
          -  No cognitive impairment or likelihood of developing cognitive impairment during study&#xD;
             participation&#xD;
&#xD;
          -  No need for palliative therapy&#xD;
&#xD;
          -  No splenomegaly&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy by cytokines, anti-tumor vaccines, or&#xD;
             monoclonal antibody therapy prior to the initiation of peripheral CD3 count&#xD;
             determination&#xD;
&#xD;
          -  No prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent biologic agents (e.g., growth factors or monoclonal antibodies)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior systemic corticosteroid therapy for more than 72 hours within the 2 weeks&#xD;
             prior to initiation of peripheral CD3 cell count determination&#xD;
&#xD;
          -  No concurrent chronic steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic therapy prior to the initiation of peripheral&#xD;
             CD3 cell count determination&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent medications for the treatment of hypertension&#xD;
&#xD;
          -  No concurrent chronic asthma medications&#xD;
&#xD;
          -  No concurrent chronic anticoagulants (e.g., high-dose warfarin, heparin, or aspirin)&#xD;
&#xD;
               -  Low-dose oral warfarin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Sportes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald E. Gress, MD</last_name>
    <affiliation>NCI - Experimental Transplantation and Immunology Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sport√®s C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res. 2010 Jan 15;16(2):727-35. doi: 10.1158/1078-0432.CCR-09-1303. Epub 2010 Jan 12.</citation>
    <PMID>20068111</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

